Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 1;12(1):167–185. doi: 10.7150/thno.61209

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

ECM/stromal and CD8 T cell-derived immune activation gene signatures are associated with poor prognosis in MPM. (A) Boxplots showing extracellular matrix (ECM)/stromal signature scores across various cancer types in TCGA. (B) Correlation analysis of the individual genes in ECM/stromal and immune activation (IA) gene sets across the TCGA MPM cohort. Transcriptomic data of treatment naïve MPM patients were obtained from TCGA (https://portal.gdc.cancer.gov/projects/TCGA). The numbers in the correlogram indicate the correlation coefficient (Spearman). Significant positive (in blue) and negative (in red) correlations are shown, with color intensity proportional to the correlation coefficient. Non-significant correlations retain a blank background. The p-value < 0.05 is considered significant. (C-D) Unadjusted Kaplan-Meier curves showing overall survival (OS) (C) and recurrence-free survival (RFS) (D) by the ratio of ECM/stromal to IA gene expression in treatment naïve MPM.